Arnold & Porter Secures Groundbreaking Biotechnology Win for Sanofi and Regeneron
Arnold Porter
JUNE 2, 2021
in one of the most closely watched biotechnology cases in recent years. In 2014, another biotechnology company sought billions of dollars in damages and a permanent injunction against the sale of Sanofi and Regeneron's lifesaving and cholesterol-reducing drug Praluent over patent disputes.
Let's personalize your content